Research use only. This compound is supplied for in-vitro laboratory research by qualified researchers. It is not for human or veterinary consumption and has not been evaluated by the FDA.
Cellular & Redox
ARA-290
Certificate pending · 10mg
10mg$65.00each
$6.50/mg
ARA-290, also called cibinetide, is an eleven-residue synthetic peptide built from the aqueous-facing residues of helix B of human erythropoietin. It is linear, and its first residue is pyroglutamate rather than a free amine.
The sequence is Pyr-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser, carried as the free acid. One point about that sequence is worth stating plainly, because it is easy to get wrong: it is not a contiguous stretch of erythropoietin. Brines and colleagues, reporting the design in PNAS in 2008, assembled it from residues that sit together on the aqueous face of helix B in the folded protein but are spread across the linear chain, so searching the erythropoietin sequence in UniProt P01588 for these eleven letters returns nothing.
The N-terminal pyroglutamate is a lactam formed from glutamate, which is why the formula registered at PubChem CID 91810664 and FDA GSRS is the free-acid undecapeptide minus ammonia. There is no acetylation, no amidation, no non-standard residue other than that pyroglutamate, and no metal coordination reported.
The molecule contains no cysteine and no sulfur atom of any kind, so there is no disulfide to form, scramble or reduce. It also contains no tryptophan, tyrosine or phenylalanine, which means there is no aromatic chromophore and absorbance at 280 nm returns nothing useful; concentration has to come from peptide-bond absorbance in the low ultraviolet, amino-acid analysis or a mass-based method.
The reported target is a heteromeric receptor complex rather than a single protein: the erythropoietin receptor EPOR (UniProt P19235) together with the shared beta-common subunit CD131, the product of CSF2RB (UniProt P32927), which Brines and colleagues named the innate repair receptor. No experimental structure of this peptide bound to that complex exists, so the contact residues are not established.
Several things commonly printed beside this compound are not established in the primary literature and are omitted here rather than estimated: there is no published solution-conformation study by circular dichroism or NMR, no quantitative solubility figure, no forced-degradation study, and no registry value for the counter-ion of supplied material. A proposed interaction with TRPV1 rests on a single secondary report and is not treated here as characterised.
Certificate pending for the 10mg lot.The signed report will be published here as soon as the laboratory returns it.
Ordering at volume or on a schedule?
Request a supply quote →Buy more of this strength and the price comes down. The store applies it at checkout - there is nothing to enter.
Free US shipping - no minimum
Tell us the lot number and what you observed. If independent testing shows a discrepancy against our published certificate, we refund the lot in full and pull it from sale pending investigation.
Tell us the lot number and what you observed. If independent testing shows a discrepancy against our published certificate, we refund the lot in full and pull it from sale pending investigation.
Certificate pending
Discreet packaging
Dispatched within one business day
Free US shipping, no minimum
Compound information
- Type
- Cellular & Redox
- CAS number
- 1208243-50-8
- Molecular formula
- C51H84N16O21
- Molecular weight
- 1257.3 g/mol
- Sequence
- Pyr-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser (QEQLERALNSS)
- Form
- Lyophilized powder
- Vial strength
- 10mg
- Catalogue number
- PX-ARA290-10MG
- Purity
- Certificate pending for this strength
Identifiers are published properties of the molecule. Values we cannot confirm are omitted rather than estimated.
Storage & handling
Lyophilized
Store lyophilized at -20C, protected from light and moisture. The sequence carries no cysteine, methionine or tryptophan, so there is no oxidation-prone side chain to guard against and the practical risks are moisture uptake by the cake and adsorptive loss from dilute solution. No published stability study exists for this peptide, so any working period should be established in the laboratory rather than assumed.
Reconstituted
Once reconstituted, keep refrigerated and avoid repeated freeze-thaw cycles.
Safety & handling
Bench handling, not a dosing guide.
Intended use
Supplied strictly as a laboratory research material for in-vitro study by qualified researchers. Not for human or veterinary use, not for ingestion or injection, and not for any clinical or diagnostic application.
Personal protective equipment
Handle with gloves, eye protection and a laboratory coat. Weigh and transfer lyophilized powder in a ventilated enclosure to avoid generating an inhalable dust.
Reconstitution
Reconstitute against the diluent and volume appropriate to your protocol, adding solvent slowly down the vial wall rather than directly onto the pellet. Do not shake. This is a handling note, not a dosing guide.
Storage after opening
Once reconstituted, refrigerate and use within the period appropriate to the material. Avoid repeated freeze-thaw cycles, which degrade peptides faster than continuous storage at the listed temperature.
Disposal
Dispose of material and containers in accordance with your institution's chemical waste procedures and applicable local regulations.
Related compounds
Research notice
Supplied as a lyophilized powder for in-vitro laboratory research only. No statement on this page describes an application, benefit, dose, route or outcome. Descriptions are structural and mechanistic, and reference data such as CAS numbers and molecular formulas is published information about the compound itself, provided for identification. No measured result is shown for this strength because a certificate has not yet been published for its lot.